Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development.
The launch comes at a time when the global market for combination cancer therapies is projected to surpass $50 billion by 2030, according to Lantern’s announcement (https://ibn.fm/3ZspZ).
The new module draws on multi-omics data – genomic, transcriptomic, and clinical –and applies machine learning models to predict which DDA-DDRi combinations are likely to produce synergistic effects in specific patient subgroups. Lantern says this approach can help design more effective, less toxic treatments and reduce development timelines and costs by up to one-third.
Panna Sharma, Lantern’s CEO and president, said the AI module aims to streamline the development of tailored cancer therapies. “This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments,” said Sharma. “By leveraging our RADR(R) platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods.”
The system’s predictive capabilities are underpinned by a peer-reviewed study published in Frontiers in Oncology that examined 221 clinical trials involving DDA-DDRi regimens (https://ibn.fm/MvmkB). From these, 89 trials with interpretable outcomes were scored based on effectiveness, safety, and biomarker-driven responses. This data was then used to train the AI model, which classifies agents into 8 DDA and 14 DDRi subclasses.
Among the study’s findings, non-PARP DDRi combinations, especially those involving WEE1 inhibitors like adavosertib paired with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials. This approach may hold particular promise for cancers with TP53 mutations, which are often difficult to treat.
The module also highlights how biomarker profiling can improve patient selection. For example, TP53 mutations and homologous recombination deficiency (“HRD”) signatures emerged as key predictors of drug response. In some regimens, reformulated drugs helped reduce toxicity. Liposomal doxorubicin, a variant with lower cardiotoxicity, was identified as a safer option for combination strategies.
Lantern has already applied the module’s insights to the design of its current clinical programs. Notably, the RADR(R) platform informed the company’s FDA-cleared Phase 1B/2 trial testing LP-184 and olaparib in triple-negative breast cancer (“TNBC”), a subtype with limited treatment options and high unmet need.
According to the company, the AI module’s architecture includes multiple specialized agents that aggregate data, classify compounds, identify biomarkers, and model outcomes. Its design allows it to evolve with new inputs, making it a continuously learning system.
Lantern is also exploring potential licensing agreements to bring the tool to a broader range of research institutions and biotech firms. The company believes the AI module could accelerate the pace of combination therapy development across various cancer types.
By embedding this technology into RADR(R), Lantern Pharma continues to position itself as a developer of data-driven approaches to oncology drug development. The module not only improves the chances of clinical success but also aligns with growing industry efforts to personalize cancer treatments based on molecular and genetic profiles.
For more information, visit the company’s website at www.LanternPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional…
Drug delivery plays a critical role in modern healthcare, but when it comes to potent…
Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent…
On average, diabetics tend to suffer from depression at higher rates than is seen in…
FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s…
Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams…